Lasiokaurin
Based on 1 publication(s) in Google Scholar
Lasiokaurin is a diterpenoid compound isolated from Isodon lasiocarpus.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 28957-08-6
- Formula: C22H30O7
- Molecular Weight:406.47
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Kinase Inhibitor Library
HY-L009
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Heterocyclic Compound Library
HY-L138
-
Cysteine Targeted Covalent Library
HY-L153
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Posttranslational Modification Library
HY-L226
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Lasiokaurin
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
10.9 μM
Compound: 8
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| A549 | IC50 |
13.47 μM
Compound: 6
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| A549 | IC50 |
6.7 μM
Compound: 19
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| A549 | IC50 |
7.6 μM
Compound: 13
|
Cytotoxicity against human A549 cells after 48 hrs by MTT method
Cytotoxicity against human A549 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| B16 | IC50 |
32.57 μM
Compound: 5
|
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| Bel-7402 | IC50 |
3.59 μM
Compound: 6
|
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| HCT-116 | IC50 |
13.48 μM
Compound: 5
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| HepG2 | IC50 |
11.94 μM
Compound: 5
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| HepG2 | IC50 |
5.67 μM
Compound: 8
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| HL-60 | IC50 |
1.8 μM
Compound: 19
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| HL-60 | IC50 |
3.2 μM
Compound: 13
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT method
Cytotoxicity against human HL60 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| K562 | IC50 |
4.92 μM
Compound: 6
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| K562 | IC50 |
521 μM
Compound: 5
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| L02 | IC50 |
22.36 μM
Compound: 6
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| L02 | IC50 |
25.39 μM
Compound: 5
|
Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| MCF7 | IC50 |
19.82 μM
Compound: 5
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| MCF7 | IC50 |
2.5 μM
Compound: 19
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| MCF7 | IC50 |
5.3 μM
Compound: 13
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| PBMC | IC50 |
>50 μM
Compound: 5
|
Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 31877536] |
| PBMC | IC50 |
>50 μM
Compound: 6
|
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| RAW264.7 | IC50 |
1.9 μM
Compound: 19
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
|
[PMID: 23819871] |
| RPMI-8226 | IC50 |
11.03 μM
Compound: 8
|
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| SGC-7901 | IC50 |
6.45 μM
Compound: 6
|
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31202992] |
| SMMC-7721 | IC50 |
2 μM
Compound: 13
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| SMMC-7721 | IC50 |
2.7 μM
Compound: 19
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| SW480 | IC50 |
2.3 μM
Compound: 13
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT method
Cytotoxicity against human SW480 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| SW480 | IC50 |
2.4 μM
Compound: 19
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
Chemical Information
-
CAS No. 28957-08-6
-
Appearance Solid
-
Molecular Weight 406.47
-
Formula C22H30O7
-
Color White to off-white
-
SMILES
O[C@]1(OC2)[C@]([C@@H]3O)(C4=O)[C@](CC[C@H]3C4=C)([H])[C@]2([C@H](CC5)OC(C)=O)[C@](C5(C)C)([H])[C@@H]1O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Lasiokaurin suppresses breast cancer growth by blocking autophagic flux and regulating cellular energy homeostasis. [Abstract]2025 Aug 7;242(Pt 3):117212. PMID: 40782951
Solvent & Solubility
DMSO : 100 mg/mL (246.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4602 mL | 12.3010 mL | 24.6021 mL | 61.5052 mL |
| 5 mM | 0.4920 mL | 2.4602 mL | 4.9204 mL | 12.3010 mL | |
| 10 mM | 0.2460 mL | 1.2301 mL | 2.4602 mL | 6.1505 mL | |
| 15 mM | 0.1640 mL | 0.8201 mL | 1.6401 mL | 4.1003 mL | |
| 20 mM | 0.1230 mL | 0.6151 mL | 1.2301 mL | 3.0753 mL | |
| 25 mM | 0.0984 mL | 0.4920 mL | 0.9841 mL | 2.4602 mL | |
| 30 mM | 0.0820 mL | 0.4100 mL | 0.8201 mL | 2.0502 mL | |
| 40 mM | 0.0615 mL | 0.3075 mL | 0.6151 mL | 1.5376 mL | |
| 50 mM | 0.0492 mL | 0.2460 mL | 0.4920 mL | 1.2301 mL | |
| 60 mM | 0.0410 mL | 0.2050 mL | 0.4100 mL | 1.0251 mL | |
| 80 mM | 0.0308 mL | 0.1538 mL | 0.3075 mL | 0.7688 mL | |
| 100 mM | 0.0246 mL | 0.1230 mL | 0.2460 mL | 0.6151 mL |
Powered by Bioz